PURPOSE OF REVIEW The purpose of this study is to review recent scientific advances relating to the natural history, cause, treatment and serum and imaging biomarkers of inclusion body myositis (IBM). RECENT FINDINGS Several theories regarding the aetiopathogenesis of IBM are being explored and new therapeutic approaches are being investigated. New diagnostic criteria have been proposed, refl...

Hereditary inclusion body myopathy type 2 (HIBM2) is a myopathy characterized by progressive muscle weakness with early adult onset. The disease is the result of a recessive mutation in the Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase gene (GNE), which results in reduced enzyme function and sialic acid levels. A majority of individuals with HIBM2 are from Iranian-Jewish or ...

Author: Helen C Lin, MD, Assistant Professor of Neurology, Medical College of Wisconsin, Milwaukee Coauthor(s): Paul E Barkhaus, MD, Professor, Department of Neurology, Medical College of Wisconsin; Director of Neuromuscular Diseases, Milwaukee Veterans Administration Medical Center; Michael P Collins, MD, Associate Professor, Department of Neurology, Medical College of Wisconsin; M Isabel Peri...

directed against RANKL, has been demonstrated to increase bone mass at both axial and peripheral skeletal sites, as well as in trabecular and cortical areas of bone [8]. It can probably prevent not only the generalized bone loss in RA, but also the joint destruction inhibiting the bone erosion [9]. On the other hand, zoledronic acid is a potent third-generation aminobisphosphonate that is thoug...

PURPOSE OF REVIEW To review the advances in our understanding of the genetics of inclusion body myositis (IBM) in the past year. RECENT FINDINGS One large genetic association study focusing on immune-related genes in IBM has refined the association within the human leukocyte antigen (HLA) region to HLA-DRB1 alleles, and identified certain amino acid positions in HLA-DRB1 that may explain this...

Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR: Dysphagia in inclusion body myositis. Am J Phys Med Rehabil 2008;87:883–889. Objective: To evaluate the clinical features, treatment strategies, and outcome of dysphagia in patients with inclusion body myositis. Design: Retrospective review of all 26 patients (20 women, 6 men, mean age of 72.2 yrs) with inclusion body myositis-associat...

A viral agent has been isolated from five fatal cases of naturally occurring inclusion body disease in three different falcon species, namely, the prairie falcon (Falco mexicanus), the red-headed falcon (F. chiquera), and the peregrine falcon (F. peregrinus). The virus has been shown to possess the physical, chemical, and biological properties of a herpesvirus and has been used to reproduce inc...